Zacks Investment Research downgraded shares of CODEXIS INC (CDXS) from N/A to NEUTRAL on May 08, 2013, with a target price of $2.50.
Codexis, Inc. is a provider of optimized biocatalysts. Biocatalysts are enzymes or microbes that initiate or accelerate chemical reactions. Biocatalysts can make existing industrial processes faster, cleaner and more efficient than current methods and have the potential to make new industrial processes possible at commercial scale. Codexis has commercialized its biocatalysts in the pharmaceutical industry and is developing biocatalysts for use in producing advanced biofuels under a multi-year research and development collaboration. The Company is also using its technology platform to pursue biocatalyst-enabled solutions in other bioindustrial markets, including carbon management, water treatment and chemicals. Codexis is based in Redwood City, California with additional offices in Budapest, Hungary Singapore and Bangalore, India.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on CODEXIS INC (CDXS),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment